secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0000950170-25-047701
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics reports FY2024 net loss of $56.6M; cash to Q3 2025; RT-114 preclinical data positive
--------------------------------------------------------------------------------

- FY2024 net loss of $56.6M vs $67.9M in 2023; cash and marketable securities $27.6M, expected to fund operations into Q3 2025.
- Preclinical data for RT-114 (GLP-1/GLP-2 dual agonist) shows 111% relative bioavailability vs subcutaneous, with bioequivalence and comparable weight loss.
- Preclinical data for semaglutide oral via RaniPill HC (RT-116) shows bioavailability, PK, and weight loss comparable to subcutaneous.
- Phase 1 study of RT-114 for obesity expected to initiate mid-2025; partnership with ProGen for co-development of RT-114.
- Impairment loss of $3.7M on construction-in-progress equipment; R&D expenses down $12.9M YoY due to workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017025047701/0000950170-25-047701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017025047701/rani-20250331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-047701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer